SCHEMBL2606237

SCHEMBL2606237

C/C(=C\c1ccc2c(c1)OCO2)N=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.56
HSD17B10 Q99714 2/20 0.56
TDP1 Q9NUW8 1/20 0.56
CYP3A4 P08684 2/20 0.54
CYP1A2 P05177 2/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
ATM Q13315 1/20 0.53
KDM4E B2RXH2 5/20 0.50
KMT2A Q03164 3/20 0.49
CRHBP P24387 1/20 0.48
CRHR2 Q13324 1/20 0.48
MAPT P10636 5/20 0.48
GRIN2D O15399 1/20 0.48
GRIN3B O60391 1/20 0.48
GRIN1 Q05586 1/20 0.48
GRIN2A Q12879 1/20 0.48
GRIN2B Q13224 1/20 0.48
GRIN2C Q14957 1/20 0.48
GRIN3A Q8TCU5 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2606235 1.00 ALDH1A1 (0.56) ALDH1A1HSD17B10TDP1CYP3A4CYP1A2
SCHEMBL25075046 1.00 ALDH1A1 (0.56) ALDH1A1HSD17B10TDP1CYP3A4CYP1A2
SCHEMBL9146862 0.82 CYP3A4 (0.59) ALDH1A1HSD17B10TDP1CYP3A4CYP1A2
SCHEMBL2524856 0.80 ALDH1A1 (0.61) ALDH1A1HSD17B10TDP1CYP3A4CYP1A2
SCHEMBL7237921 0.80 CYP1A2 (0.57) ALDH1A1HSD17B10TDP1CYP3A4CYP1A2
SCHEMBL1254172 0.80 ALDH1A1 (0.61) ALDH1A1HSD17B10TDP1CYP3A4CYP1A2
SCHEMBL9609537 0.80 CYP1A2 (0.57) ALDH1A1HSD17B10TDP1CYP3A4CYP1A2
SCHEMBL28491533 0.79 CYP3A4 (0.56) ALDH1A1HSD17B10TDP1CYP3A4CYP1A2
SCHEMBL7820555 0.79 CYP1A2 (0.63) ALDH1A1HSD17B10TDP1CYP3A4CYP1A2
SCHEMBL25075069 0.79 ALDH1A1 (0.54) ALDH1A1HSD17B10TDP1CYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2468276-B1 Nitrostyrene derivatives having antimicrobial action BIODIEM LTD (AU) 2015-11-11 EP disclosed
US-8158664-B2 Antimicrobial and radioprotective compounds BIODIEM LTD. (AU) 2012-04-17 US disclosed
US-20100292317-A1 ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS BIODIEM LTD. (AU) 2010-11-18 US disclosed
US-20090012137-A1 administering microbiocides such as 3,4-methylenedioxy- beta -nitrostyrene, for the treatment of urogenital disorders caused by Candida, Neisseria, Chlamydia or Trichomonas; side effect reduction of radiotherapy BIODIEM LTD. (AU) 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292317-A1 ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS RAD51, BRCA1, XPA ALDH1A1 1984/4885HSD17B10 3083/4885TDP1 620/4885
US-20090012137-A1 administering microbiocides such as 3,4-methylenedioxy- beta -nitrostyrene, for the treatment of urogenital disorders caused by Candida, Neisseria, Chlamydia or Trichomonas; side effect reduction of radiotherapy TUBB1, UGT1A1, CYP1A1 ALDH1A1 770/4885HSD17B10 1395/4885TDP1 188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.